Considerations To Know About ABBV-744 BRD4 inhibitor cancer therapy efficacy
In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will get treatment till disease progression or perhaps the contributors are not able to tolerate the study drugs.Doable new techniques to the diagnosis and treatment of AML. (A) The identification of Tremendou